1. Home
  2. VMC vs ARGX Comparison

VMC vs ARGX Comparison

Compare VMC & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VMC
  • ARGX
  • Stock Information
  • Founded
  • VMC 1909
  • ARGX 2008
  • Country
  • VMC United States
  • ARGX Netherlands
  • Employees
  • VMC N/A
  • ARGX N/A
  • Industry
  • VMC Mining & Quarrying of Nonmetallic Minerals (No Fuels)
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VMC Industrials
  • ARGX Health Care
  • Exchange
  • VMC Nasdaq
  • ARGX Nasdaq
  • Market Cap
  • VMC 35.0B
  • ARGX 35.1B
  • IPO Year
  • VMC N/A
  • ARGX 2017
  • Fundamental
  • Price
  • VMC $255.93
  • ARGX $542.15
  • Analyst Decision
  • VMC Strong Buy
  • ARGX Strong Buy
  • Analyst Count
  • VMC 12
  • ARGX 19
  • Target Price
  • VMC $303.82
  • ARGX $709.29
  • AVG Volume (30 Days)
  • VMC 1.0M
  • ARGX 272.3K
  • Earning Date
  • VMC 08-05-2025
  • ARGX 07-24-2025
  • Dividend Yield
  • VMC 0.77%
  • ARGX N/A
  • EPS Growth
  • VMC 3.11
  • ARGX N/A
  • EPS
  • VMC 7.06
  • ARGX 15.94
  • Revenue
  • VMC $7,506,600,000.00
  • ARGX $2,643,062,000.00
  • Revenue This Year
  • VMC $11.05
  • ARGX $61.64
  • Revenue Next Year
  • VMC $7.02
  • ARGX $32.00
  • P/E Ratio
  • VMC $36.06
  • ARGX $31.16
  • Revenue Growth
  • VMC N/A
  • ARGX 82.13
  • 52 Week Low
  • VMC $215.08
  • ARGX $379.39
  • 52 Week High
  • VMC $298.31
  • ARGX $678.21
  • Technical
  • Relative Strength Index (RSI)
  • VMC 39.65
  • ARGX 37.26
  • Support Level
  • VMC $259.24
  • ARGX $537.75
  • Resistance Level
  • VMC $261.76
  • ARGX $589.06
  • Average True Range (ATR)
  • VMC 4.24
  • ARGX 11.79
  • MACD
  • VMC -1.52
  • ARGX -3.95
  • Stochastic Oscillator
  • VMC 14.53
  • ARGX 8.10

About VMC Vulcan Materials Company (Holding Company)

Vulcan Materials is the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). Its largest markets include Texas, California, Virginia, Tennessee, Georgia, Florida, North Carolina, and Alabama. In 2024, Vulcan sold 219.9 million tons of aggregates, 13.6 million tons of asphalt mix, and 3.6 million cubic yards of ready-mix. As of Dec. 31, 2023, the company had nearly 16 billion tons of aggregates reserves.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: